home / stock / drma / drma quote
Last: | $1.64 |
---|---|
Change Percent: | -3.53% |
Open: | $1.7 |
Close: | $1.70 |
High: | $2.58 |
Low: | $1.62 |
Volume: | 1,008,226 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.64 | $1.7 | $1.7 | $2.58 | $1.62 | 1,008,226 | 07-23-2024 |
$1.7 | $1.63 | $1.7 | $1.78 | $1.61 | 40,127 | 07-22-2024 |
$1.7253 | $1.82 | $1.7253 | $1.8264 | $1.61 | 75,532 | 07-19-2024 |
$1.8113 | $1.93 | $1.8113 | $1.9781 | $1.8113 | 51,780 | 07-18-2024 |
$1.9895 | $1.9 | $1.9895 | $2 | $1.8 | 150,894 | 07-17-2024 |
$2 | $2.19 | $2 | $2.23 | $1.87 | 72,669 | 07-16-2024 |
$2.19 | $2.3 | $2.19 | $2.3 | $2.17 | 63,702 | 07-15-2024 |
$2.28 | $2.34 | $2.28 | $2.38 | $2.2317 | 210,552 | 07-12-2024 |
$2.58 | $2.3 | $2.58 | $2.86 | $2.21 | 1,109,106 | 07-11-2024 |
$2.2 | $2.4 | $2.2 | $2.5725 | $2.13 | 49,931 | 07-10-2024 |
$2.43 | $2.314 | $2.43 | $2.9 | $2.2401 | 105,544 | 07-09-2024 |
$2.31 | $2.49 | $2.31 | $2.49 | $2.11 | 25,216 | 07-08-2024 |
$2.36 | $2.28 | $2.36 | $2.67 | $2.17 | 52,926 | 07-05-2024 |
$2.23 | $2.16 | $2.23 | $2.31 | $2.15 | 13,831 | 07-04-2024 |
$2.23 | $2.16 | $2.23 | $2.31 | $2.15 | 13,831 | 07-03-2024 |
$2.23 | $2.3 | $2.23 | $2.41 | $2.23 | 22,160 | 07-02-2024 |
$2.29 | $2.297 | $2.29 | $2.44 | $2.28 | 20,784 | 07-01-2024 |
$2.39 | $2.55 | $2.39 | $2.55 | $2.16 | 44,404 | 06-28-2024 |
$2.33 | $2.58 | $2.33 | $2.6632 | $2.099 | 70,220 | 06-27-2024 |
$2.63 | $2.7 | $2.63 | $2.7 | $2.5 | 30,797 | 06-26-2024 |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
- STAR-1 topline results expected in first quarter of 2025 - - About 30 million acne patients seek treatment in the U.S. each year - - DMT310, if approved, could be the first once-weekly topical product for the treatment of acne - SAN DIEGO, CA / ACCESSWIRE / July 17, 2024 / Derm...
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...